Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study.
Collet, Jean-Philippe; Funck-Brentano, Christian; Prats, Jayne; Salem, Joe-Elie; Hulot, Jean-Sébastien; Guilloux, Edith; Hu, Ming-yi; He, Kan; Silvain, Johanne; Gallois, Vanessa; Brugier, Delphine; Anzaha, Ghalia; Galier, Sophie; Nicolas, Nathalie; Montalescot, Gilles.
Am J Cardiovasc Drugs
; 16(1): 43-53, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-26386578
Genetics of platelet inhibitor treatment.
Early P2Y12 inhibition in ST-segment elevation myocardial infarction: Bridging the gap.
Influence of Diabetes Mellitus and Cigarette Smoking on Variability of the Clopidogrel-Induced Antiplatelet Effect and Efficacy of Active Management of the Target P2Y12 Reaction Unit Range in Patients Undergoing Neurointerventional Procedures.
Role of phenotypic and genetic testing in managing clopidogrel therapy.
A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease.
Clopidogrel-Associated Neutropenia: Case Report and Review of the Literature.
Comparison of pharmacodynamics between low dose ticagrelor and clopidogrel after loading and maintenance doses in healthy Korean subjects.
The impact of switching P2Y12 receptor inhibitor therapy during index hospitalization: a systematic review.
International Expert Consensus on Switching Platelet P2Y<sub>12</sub> Receptor-Inhibiting Therapies.
CYP2C19*17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel.